Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II stepwise progression in the treatment of cardiogenic shock with adrenaline
2014-002672-86Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Oct 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epinephrine in cardiogenic shock, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoints: number of successes and survival at 60 days. Started Oct 2014; status: completed.
02
Drugs
epinephrine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2014-002672-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002672-86.